pipette
ESEspañol

Strategies to establish a biologically defined Parkinson's disease cohort prior to the onset of clinically significant motor symptoms

E. G. Brown, H. Blumenau, D.-E. Lafontant, A. R. Nair, N. Johnson, R. N. Alcalay, L. M. Chahine, C. S. Coffey, R. D. Dobkin, T. Foroud, D. Galasko, K. Merchant, B. Mollenhauer, K. L. Poston, A. Siderowf, C. M. Tanner, D. Weintraub, K. Marek, T. Simuni, T. F. Tropea, Parkinson's Precision Medicine Initiative

Preprint

In the authors' words

Identifying individuals at risk for neurodegeneration is a priority for clinical trials. Parkinson's Precision Medicine Initiative (PPMI) deploys strategies to enroll individuals before typical clinical Parkinson's disease symptoms: recruiting polysomnogram-confirmed REM sleep behavior disorder (RBD) and central identification of hyposmia via smell testing. Groups were divided into RBD with and without hyposmia (RBD+Hyposmia, RBD-Hyposmia) and hyposmia with and without self-reported dream enactment behavior (Hyposmia+DEB, Hyposmia-DEB). Participants underwent clinical and biomarker testing including CSF alpha-synuclein seed amplification assay (CSFaSynSAA) and dopamine transporter imaging. While all enrollment strategies showed robust enrichment for CSFaSynSAA positivity, RBD+Hyposmia and Hyposmia+DEB were more likely CSFaSynSAA+ (94% and 85%) vs RBD-Hyposmia (40%) and Hyposmia-DEB (55%). Among CSFaSynSAA+, RBD+Hyposmia and Hyposmia+DEB had more mood, autonomic, and cognitive symptoms than Hyposmia-DEB. PPMI identified a large biologically-defined early neuronal synucleinopathy cohort and demonstrated biomarker and multi-domain clinical heterogeneity within CSFaSynSAA+ individuals prior to symptom onset.

Main resultThe abstract does not state a limitation.

Appeared: Thursday, October 29. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.26.26366535